Arthritis Associates PLLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$4,546	1
2024	Research	$52,108	7
2023	Research	$19,412	3
2022	Research	$75	1
2021	Research	$56,837	12
2020	Research	$75,897	22
2019	Research	$80,787	18

Breakdown

Who paid Research payments · program years 2019–2025

Gilead Sciences, Inc. $172,932 38 payments
AbbVie, Inc. $65,413 22 payments
Eli Lilly and Company $46,771 3 payments
GlaxoSmithKline, LLC. $4,546 1 payment

Studies the money was for Research payments · program years 2019–2025

Taltz Psa Observational Study $35,322 1 payment
M16-063 $20,959 9 payments
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to Biologic and/or Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs (b/tsDMARDs) $17,957 3 payments
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $16,348 6 payments
Taltz Psa Observational Study $11,276 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $9,915 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $8,816 1 payment
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) $8,566 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $6,867 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $6,793 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.